Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma

NCT01458249 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT01458249
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01458249 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
February 29, 2016
Enrollment
52 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma